Mersana Therapeutics, Inc.
222 articles about Mersana Therapeutics, Inc.
-
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
2/28/2024
Mersana Therapeutics, Inc. provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Mersana Therapeutics to Present at Upcoming March 2024 Investor Conferences
2/27/2024
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at the following upcoming investor conferences.
-
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
2/21/2024
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024.
-
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference
2/1/2024
Mersana Therapeutics, Inc. today announced that members of management will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024 at 11:30 a.m. ET.
-
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
1/5/2024
Mersana Therapeutics, Inc. (NASDAQ: MRSN) today announced business updates, its expected 2024 milestones and its upcoming presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
12/1/2023
Mersana Therapeutics, Inc. announced that on December 1, 2023, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit award to acquire 12,205 shares of its common stock, to one new employee whose employment commenced in November 2023.
-
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
11/7/2023
Mersana Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2023.
-
The regulator has released Mersana Therapeutics’ antibody-drug conjugate XMT-2056 from its clinical hold, allowing the biotech to proceed with Phase I studies of the candidate with a lower starting dose.
-
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
10/31/2023
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023.
-
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
10/31/2023
Mersana Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company’s Phase 1 clinical trial of XMT-2056.
-
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
8/8/2023
Mersana Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2023.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 04, 2023
8/4/2023
Mersana Therapeutics, Inc. announced that on August 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 38,775 shares of its common stock and restricted stock unit awards to acquire an aggregate of 27,655 shares of its common stock, to two new employees whose employment commenced in July 2023.
-
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
7/27/2023
Mersana Therapeutics, Inc. today announced that the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary endpoint.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2023
7/6/2023
Mersana Therapeutics, Inc. announced that on July 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 38,775 shares of its common stock and restricted stock unit awards to acquire an aggregate of 82,260 shares of its common stock, to 5 new employees whose employment commenced in June 2023.
-
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical TrialsUPLIFT top-line data expected by early August
6/15/2023
Mersana Therapeutics, Inc. announced that the U.S. Food and Drug Administration has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company’s ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer.
-
Following cases of serious bleeding in patients, five of which were fatal, the regulator has put Mersana’s investigational antibody-drug conjugate UpRi on partial clinical hold in two ovarian cancer trials.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2023
6/2/2023
Mersana Therapeutics, Inc. announced that on June 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 38,775 shares of its common stock and restricted stock unit awards to acquire an aggregate of 48,520 shares of its common stock, to four new employees whose employment commenced in May 2023.
-
Mersana Therapeutics to Present at Upcoming Investor Conferences - May 24, 2023
5/24/2023
Mersana Therapeutics, Inc. today announced that members of management will present at the following upcoming investor conferences.
-
Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
5/9/2023
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, provided a business update and reported financial results for the first quarter ended March 31, 2023.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023
5/4/2023
Mersana Therapeutics, Inc. announced that on May 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 77,550 shares of its common stock and restricted stock unit awards to acquire an aggregate of 65,715 shares of its common stock, to four new employees whose employment commenced in April 2023.